News and Press Releases
Press releases
Patient Six Cancer-Free Twelve Months After Single Anti-Cancer Treatment
Press ReleaseResults of Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) Clinical Study Demonstrate a 66% Complete Response (“CR”) at the Therapeutic Dose (0.70 mg/cm2) 360 Days Post Treatment Toronto, Ontario –April 2, 2019 Theralase ...
Theralase’s Phase IB Clinical Study to be Presented at the 17th International Photodynamic Association World Congress
Press ReleaseToronto, Ontario – March 26, 2019 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Pho...
Theralase® Granted United States Patent to Destroy Cancer Cells with X-Ray Activated Photo Dynamic Compounds
Press ReleaseToronto, Ontario – March 4, 2019 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Pho...
Theralase® Achieves Third Place in the Clean Technology and Life Sciences Category on the 2019 TSX Venture 50
Press ReleaseToronto, Ontario – February 28, 2019 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated...
Theralase® Announces Appointment of New Chief Executive Officers
Press ReleaseToronto, Ontario – February 25, 2019 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated...
Theralase® Patient Five Cancer-Free Twelve Months After Single Anti-Cancer Treatment
Press ReleaseToronto, Ontario – January 31, 2019 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated P...
Theralase® Patient Six Cancer-Free at Nine Months After Single Anti-Cancer Treatment
Press ReleaseToronto, Ontario – January 30, 2019 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated P...
Theralase® Completes $1.4 M Private Placement Equity Financing
Press ReleaseToronto, Ontario – January 9, 2019 Theralase Technologies Inc. (“Theralase®” or “Company”) (TSXV: TLT) (OTCQB: TLTFF) is pleased to announce that it has closed its previously announced non-brokered privateplacement offering (...
Health Canada Grants ITA Approval to Commence Phase II Clinical Study
Press ReleaseToronto, Ontario – December 10, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”)(TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated P...
Theralase’s Rutherrin® Photo Dynamic Therapy Induces Immune Response to Destroy Human Brain Cancer Cells
Press ReleaseRutherrin® mediated Photo Dynamic Therapy improves cancer specific immune responses by switching the so called “Don’t eat me” signal that cancer cells use to trick the immune system into the “Eat me” signal on treated human gl...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
